Navigation Links
Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
Date:9/29/2009

BEDFORD, Mass., Sept. 29 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced it has received CE marking approval for its ThinPrep® integrated imager. The ThinPrep integrated imager was introduced and on display at the 35th European Congress of Cytology this week in Lisbon, Portugal.

The integrated imager represents the latest innovation in cervical cancer screening by combining proven ThinPrep imaging technology and slide review into a single, convenient stand-alone device. This exciting new product offering allows laboratories of all sizes to benefit from clinical advantages of ThinPrep imaging for cervical screening.

"This represents a tremendous opportunity for Hologic and our current and future laboratory partners throughout Europe," said Howard Doran, senior vice president, diagnostics products for Hologic. "The ThinPrep integrated imager is designed to provide the small and medium volume laboratory access to the most effective and efficient cytology screening technology available, while allowing them the flexibility to address their specific productivity and throughput needs." The majority of laboratories in Europe would fall into the small or medium category.

The integrated imager analyzes a ThinPrep Pap test slide in approximately 90 seconds, during which time each cell and cell cluster is scanned. Using optical density analysis, the integrated imager identifies diagnostically-relevant cells or cell groups and then stores coordinates of the 22 fields of interest. These 22 fields of interest are presented to the cytotechnologist for interpretation. If no abnormalities are identified by the cytotechnologist, the slide can be signed out as negative or proceed through the laboratory quality control system. A complete slide review is required if the user detects any suspicious cells within the 22 fields of view. This dual review process combines human interpretative expertise with the power of computer imaging.

Hologic's experience working with ThinPrep Pap test users contributed significantly to the integrated imager development. Every feature is designed to enable the cytotechnologist to perform slide review effectively and efficiently. The integrated imager can also be used as a conventional microscope saving valuable lab space.

CE marking approval allows Hologic to market the ThinPrep integrated imager in the 27 countries of the European Union (EU) and three of the four member states of the European Free Trade Association (EFTA). CE marking is recognized in many countries outside the European Economic Area giving Hologic the ability to supply systems to a number of markets internationally. The ThinPrep integrated imager is currently not approved by the U.S. Food and Drug Administration.

About Hologic

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.

Forward-Looking Statement Disclaimer

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the ThinPrep Pap test, ThinPrep imaging system and the ThinPrep integrated imager. There can be no assurance the system will achieve the benefits described herein and that such benefits will be replicated in any particular manner by a particular laboratory as the actual effect of the use of the ThinPrep Pap test, ThinPrep imaging system and the ThinPrep integrated imager can only be determined on a case-by-case basis depending on the particular laboratory, screening personnel and patient sample in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.

Hologic and ThinPrep are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

    Contact:  For Investors:                            For Media:
              Deborah R. Gordon                         Jeff Keene
              Vice President, Investor Relations        Product Marketing
              Hologic, Inc.                             Hologic, Inc.
              (781) 999-7716                            (508) 263-8957

SOURCE Hologic, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
2. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
5. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
6. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
7. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
8. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
9. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
10. Cytopias CYT387 Receives FDA Clearance to Start US Clinical Trials
11. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... 2016   Pairnomix, LLC, a genetic research company ... by the White House, today announced that findings from its ... of candidate therapies for a patient with epileptic encephalopathy caused ... presented at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process ...
(Date:12/4/2016)... , Dec. 3, 2016  Results from the Phase ... an anti-P-selectin antibody, reduced the median annual rate of ... placebo (1.63 vs 2.98, p=0.010) in patients with or ... the data are being featured in the official press ... Hematology (ASH) Annual Meeting and presented during the Plenary ...
(Date:12/4/2016)... 3, 2016  Findings from a Novartis clinical ... an investigational chimeric antigen receptor T cell (CAR ... adult patients with B-cell acute lymphoblastic leukemia (ALL) ... at the 58th American Society of Hematology (ASH) ... The global Phase II study found that 82% ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... 02, 2016 , ... Dr. Raffi Hovsepian, a leading plastic, ... 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The prestigious ... experience, and professional associations. , One the most frequently honored surgeons in ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet is proud to announce the ... the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and ... 6 years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference will ... Spa in Honolulu, offering local frontline clinicians the opportunity to extend their certified ... demand for supplemental training related to pain management has surged dramatically in recent ...
(Date:12/2/2016)... ... 02, 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year ... natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its ... available in several ShopRite and FoodTown stores in NJ and received rave comments from ...
(Date:12/2/2016)... ... , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, has ... Prophecy. Yisrayl says this generation, known as the Last Generation, started in 1934 A.Y. ... line up exactly with Bible Prophecy – a protected way for those who will ...
Breaking Medicine News(10 mins):